Abstract
Snakebite is a neglected tropical disease that causes considerable death and disability in the tropical world. Although snakebite can cause a variety of pathologies in victims, haemotoxic effects are particularly common and are typically characterised by haemorrhage and/or venom-induced consumption coagulopathy. Antivenoms are the mainstay therapy for treating the toxic effects of snakebite, but despite saving thousands of lives annually, these therapies are associated with limited cross-snake species efficacy due to venom variation, which ultimately restricts their therapeutic utility to particular geographical regions. In this study, we sought to explore the potential of ssDNA aptamers as toxin-specific inhibitory alternatives to antibodies. As a proof of principle model, we selected snake venom serine protease toxins, which are responsible for contributing to venom-induced coagulopathy following snakebite envenoming, as our target. Using SELEX technology, we selected ssDNA aptamers against recombinantly ex
| Original language | English |
|---|---|
| Article number | 469 |
| Pages (from-to) | e469 |
| Journal | Toxins |
| Volume | 14 |
| Issue number | 7 |
| Early online date | 8 Jul 2022 |
| DOIs | |
| Publication status | E-pub ahead of print - 8 Jul 2022 |
Keywords
- in vitro assays
- recombinant toxins
- SELEX selection
- snake venom serine proteases
- snakebite envenoming
- ssDNA aptamers